3VG Stock Chart & Stats
€2.74
-€0.06(-8.12%)
At close: 4:00 PM EST
€2.74
-€0.06(-8.12%)
Day’s Range― - ―
52-Week Range€1.51 - €4.49
Previous CloseN/A
Volume0.00
Average Volume (3M)596.00
Market Cap
€61.07M
Enterprise Value€37.19M
Total Cash (Recent Filing)€7.77M
Total Debt (Recent Filing)€2.88M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding14,472,778
10 Day Avg. Volume242
30 Day Avg. Volume596
Financial Highlights & Ratios
PEG Ratio-2.04
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Neurological Drug PipelineA focused CNS pipeline targeting rare or severe neurological diseases can support differentiated development opportunities and meaningful medical need. Progress through clinical development may create partnering or licensing potential if programs show efficacy.
Cash Burn ImprovementLower operating and free-cash-flow consumption versus 2023 indicates some progress in cost control or spending discipline. While cash generation remains negative, a sustained improvement could extend the funding runway and reduce near-term financing pressure.
Equity Returned To PositiveThe return to positive shareholder equity in 2025 partially improves balance-sheet resilience after the prior deficit. This provides a stronger capital base for continued clinical development, although accumulated losses and funding needs remain material.
Bears Say
No Visible Commercial RevenueZero revenue leaves the company without a dependable operating income stream and increases reliance on clinical milestones, partnerships, grants, or capital markets. Until a candidate is approved and commercialized, revenue visibility remains structurally weak.
Persistent UnprofitabilityRecurring losses and deeply negative operating results show that the current business model is not self-funding. Continued clinical development will likely require substantial investment before any potential product revenue can offset research and operating costs.
Funding-dependent Balance SheetPersistent cash burn combined with meaningful debt and declining assets limits financial flexibility. External financing remains necessary to fund operations, creating dilution, refinancing, and execution risks if capital becomes harder to secure.
Theranexus SA News
3VG FAQ
What was Theranexus SA’s price range in the past 12 months?
Theranexus SA lowest stock price was €1.51 and its highest was €4.49 in the past 12 months.
What is Theranexus SA’s market cap?
Theranexus SA’s market cap is €61.07M.
When is Theranexus SA’s upcoming earnings report date?
Theranexus SA’s upcoming earnings report date is Sep 24, 2026 which is in 27 days.
How were Theranexus SA’s earnings last quarter?
Currently, no data Available
Is Theranexus SA overvalued?
According to Wall Street analysts Theranexus SA’s price is currently Overvalued.
Does Theranexus SA pay dividends?
Theranexus SA does not currently pay dividends.
What is Theranexus SA’s EPS estimate?
Theranexus SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theranexus SA have?
Theranexus SA has 14,472,778 shares outstanding.
What happened to Theranexus SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theranexus SA?
Currently, no hedge funds are holding shares in DE:3VG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theranexus SA
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
Technical Analysis
GenSight Biologics SA
―
AB Science SA
―
Sensorion SAS
―
Intrasense SA
―
MedinCell SA
―